RazaviPVingopoulosFGarciaM, et al. Impaired visual function in posterior vitreous detachment assessed with the active-learning quantitative contrast sensitivity function test. J Vitreoretin Dis. 2024;8(5):533–539.
4.
GirgisJMBaumalCRWitkinAJ, et al. Update on retinal drug safety: proceedings of the ASRS ReST Committee Webinar Part 1. J Vitreoretin Dis. 2024;8(5):500–507.
5.
BurgettLAggarwalNLatonaJDribanMChhablaniJMaturiRK.Retrospective large database study of central serous chorioretinopathy treatments and visual outcomes analysis in the United States. J Vitreoretin Dis. 2024;8(5):508–516.
6.
AgarwalAGhaziNEl GhrablyI, et al. Use of color channel optimization in 3D heads-up vitrectomy vs standard operating microscope for macular surgeries. J Vitreoretin Dis. 2024;8(5):517–523.
7.
AllenAZhengYLeeT, et al. Risk factors for progression of vitreomacular traction to macular hole. J Vitreoretin Dis. 2024;8(5):524–532.
8.
MishraAVMartensRLohGKSomaniRGreveMDJSeamoneME.Clinical outcomes of pars plana vitrectomy and polytetrafluoroethylene (Gore-Tex) scleral fixation of a monofocal aspheric intraocular lens (Akreos AO60). J Vitreoretin Dis. 2024;8(5):540–545.
9.
HwangHHBotsfordBWLenisTL, et al. Adverse events associated with 3 vitrectomy platforms reported to the US FDA MAUDE database. J Vitreoretin Dis. 2024;8(5):546–553.
10.
TienKXRomoEAdamMK.Pars plana vitrectomy without intravenous anesthesia: technique, safety, and outcomes. J Vitreoretin Dis. 2024;8(5):554–557.
11.
CakirYSassineAMatarK, et al. Assessment of macular hole closure speed using trans-tamponade OCT and 3-dimensional macular hole segmentation in the DISCOVER study. J Vitreoretin Dis. 2024; 8(5):558–564.
12.
GhalibafanSCaiLZChouBGPatelNAShaheenAYannuzziNA.Cross-sectional survey of vitreoretinal surgery fellowship training in secondary intraocular lens placement. J Vitreoretin Dis. 2024;8(5):565–570.
13.
JosephSWooJRobbinsCB, et al. Longitudinal assessment of peripapillary microvasculature using optical coherence tomography angiography in cognitively normal adults. J Vitreoretin Dis. 2024;8(5):571–576.
14.
WykoffCCKuppermannBDRegilloCD, et al. Extended intraocular drug-delivery platforms for the treatment of retinal and choroidal diseases. J Vitreoretin Dis. 2024;8(5):577–586.
15.
ValikodathNGLiJDRaynorWIzattJATothCAVajzovicL.Intraoperative OCT-guided volumetric measurements of subretinal therapy delivery in humans. J Vitreoretin Dis. 2024;8(5):587–592.
16.
Medina-MedinaSRamírez-EstudilloAJuárezSR.OCT features of the donor area in autologous retinal transplant surgery for macular hole. J Vitreoretin Dis. 2024;8(5):593–596.
BudoffGDillonABAuAKriegerAESchwartzSD.Unexplained acute total loss of vision after primary scleral buckle surgery. J Vitreoretin Dis. 2024;8(5):600–604.
19.
MazzeoTJMMBarbosaGCSFilhoRSFreireRCMMachadoCGGomesAMV. Successful closure of an idiopathic macular hole with topical therapy after failed surgery. J Vitreoretin Dis. 2024;8(5):605–608.
DavisABlumenthalJHoyekSRizzoJFIIIPatelNA.Atypical presentation of vitreous inflammation in a patient with hypertensive retinopathy. J Vitreoretin Dis. 2024;8(5):614–617.
22.
SreenivasanJAnandARVarmaSGarima. Challenging case of postoperative Nocardia endophthalmitis. J Vitreoretin Dis. 2024; 8(5):618–621.
23.
HsuJBrownJMallickA, et al. Successful treatment of central retinal artery occlusion with tissue plasminogen activator followed by recurrent retinal ischemia. J Vitreoretin Dis. 2024;8(5):622–626.
